BCABBioAtla, Inc.vs its industry peers
A metric-by-metric comparison of BioAtla, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAB본 종목 | — | 0.1x#3 | — | — | — | -14.6%#8 | -19768.3%#7 | — | — | — | -95.4%#14 | — |
| AIM | $7M#1 | — | 0.8x#5 | 74.3x#7 | -48.2%#6 | 19.4%#5 | -13254.5%#6 | -180.2%#5 | -7934.7%#6 | — | -91.7%#11 | — |
| CELZ | $6M#2 | — | 0.7x#4 | 960.9x#8 | -45.5%#4 | -9.1%#7 | -102380.2%#9 | -69.3%#2 | -66.1%#2 | 3#2 | -75.0%#9 | — |
| ZIVO | $5M#3 | — | — | 31.3x#5 | 468.6%#1 | -72.1%#10 | -8498.9%#3 | — | — | — | 0.0%#5 | — |
| BKHAR | $4M#4 | — | — | — | — | -30.6%#9 | — | — | — | — | 592.8%#1 | 1204.0%#1 |
| PMCB | $4M#5 | — | 0.2x#2 | — | — | -163.4%#11 | — | -70.6%#3 | -56.0%#1 | — | -61.2%#7 | — |
| LIMNW | $4M#7 | — | 12.5x#7 | — | — | -187.8%#12 | — | -3395.2%#7 | -170.3%#4 | — | -65.3%#8 | — |
| CLDI | $3M#9 | 0.0x#2 | 1.0x#6 | 68.9x#6 | — | 10.1%#6 | -44977.8%#8 | -635.4%#6 | — | — | -95.3%#13 | — |
| WINT | $3M#8 | — | — | 17.1x#3 | -88.9%#7 | 91.2%#2 | -13201.5%#5 | — | -308.7%#5 | — | -75.1%#10 | 19.4%#2 |
| ESLAW | $3M#10 | — | — | — | — | — | — | — | — | — | 5.4%#4 | — |
| SABSW | $3M#11 | 0.1x#5 | 0.0x#1 | — | -100.0%#8 | 138.9%#1 | — | 6.2%#1 | — | — | -24.9%#6 | — |
| CEROW | $3M#12 | — | — | — | — | — | — | — | — | — | 145.3%#2 | 4.9%#3 |
| CRIS | $2M#13 | 0.1x#4 | 0.5x#3 | 0.3x#2 | -13.4%#3 | 82.5%#3 | -60.5%#1 | -161.5%#4 | -87.3%#3 | — | -96.6%#15 | — |
| SLXN | $2M#14 | 0.0x#1 | 42.9x#8 | — | — | 27.9%#4 | — | -27072.7%#8 | — | — | -99.1%#16 | — |
| SCLXW | $1M#15 | — | — | 0.0x#1 | -46.5%#5 | -413.8%#13 | -1143.7%#2 | — | — | 4#1 | 107.0%#3 | — |
| VIVS | $4M#6 | — | — | 31.2x#4 | -9.0%#2 | -456.4%#14 | -8768.7%#4 | — | — | — | -94.2%#12 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice